Kaazan Patricia, Seow Warren, Yong Shaanan, Heilbronn Leonie K, Segal Jonathan P
Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia.
South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
Biomedicines. 2023 Dec 8;11(12):3256. doi: 10.3390/biomedicines11123256.
Obesity is prevalent in the inflammatory bowel disease (IBD) population, particularly in newly developed countries where both IBD and obesity in the general population are on the rise. The role of obesity in the pathogenesis of IBD was entertained but results from available studies are conflicting. It does, however, appear to negatively influence disease course whilst impacting on our medical and surgical therapies. The pro-inflammatory profile of the visceral adipose tissue might play a role in the pathogenesis and course of Crohn's Disease (CD). Interestingly, isolating the mesentery from the surgical anastomosis using a KONO-S technique significantly decreases anastomotic recurrence rate. Anti-obesity therapy is not widely used in IBD but was suggested as an adjunctive therapy in those patients. In this review, we aimed to highlight the epidemiology of obesity in IBD and to describe its influence on disease course and outcomes.
肥胖在炎症性肠病（IBD）人群中很普遍，尤其是在一些新兴国家，这些国家普通人群中的IBD和肥胖发生率都在上升。肥胖在IBD发病机制中的作用一直受到关注，但现有研究结果相互矛盾。然而，肥胖似乎确实会对疾病进程产生负面影响，同时也会影响我们的药物和手术治疗。内脏脂肪组织的促炎特性可能在克罗恩病（CD）的发病机制和病程中起作用。有趣的是，使用KONO-S技术将肠系膜与手术吻合口分离可显著降低吻合口复发率。抗肥胖疗法在IBD中并未广泛应用，但有人建议将其作为这些患者的辅助治疗方法。在本综述中，我们旨在强调IBD中肥胖的流行病学情况，并描述其对疾病进程和结局的影响。
